Market Intelligence, Clinical Progress, and High-Purity Reagents for Severe Inflammation & Sepsis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD14 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD14 Soluble / Mutant Protein & CD14 ECD-Fc / His Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD14 Products |
| Gene Delivery | CD14 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. GPI-anchored construct preserves surface expression. |
View CD14 Products |
| Benchmark Ab | Anti-CD14 (Sequence of Atibuclimab/IC-14) Recombinant positive control for LPS inhibition assays. |
View CD14 Products |
| Validator | CD14 siRNA Set For knockdown verification in TLR4 signaling studies. |
View CD14 Products |
| Related Target: TLR4 | Toll-Like Receptor 4 Primary signaling partner. Required for CD14-mediated LPS recognition. |
View TLR4 Products |
| Related Target: LY96 (MD-2) | MD-2 Protein Essential co-receptor with TLR4 for LPS binding. Critical for pathway validation. |
View LY96 Products |
| Related Target: LBP | LPS Binding Protein Upstream transfer protein. Functional counter-screen for specificity. |
View LBP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity; theoretical MW confirmed by SDS-PAGE |
| Preserving Native Glycosylation | HEK293 Expressed (Native Glycosylation), Theoretical MW verified |
| GPI-Anchor vs Soluble Form Distinction | Full-length Lentivirus (GPI-anchored) and ECD-Fc (Soluble mimic) both available. Sequence Verified. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks; MD-2 counter-screen for off-target |
Live CD14 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD14 therapeutics is intensifying, with major players shifting focus from traditional sepsis management to acute respiratory distress syndrome (ARDS), neuroinflammation, and precision myeloid modulation. Early-phase anti-CD14 antibodies for sepsis demonstrated safety, driving exploration of broader indications including non-alcoholic steatohepatitis (NASH), inflammatory bowel disease (IBD), and tumor-associated macrophage (TAM) reprogramming in solid tumors. Current R&D also highlights soluble CD14 (sCD14) as a biomarker and therapeutic decoy for sterile inflammation and neurodegenerative diseases. As first-generation therapies reach the clinic, next-wave R&D targets optimal blockade of the LPS-TLR4-CD14 axis without broadly compromising immune competence.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Blocking mAb) | Implicit Bioscience, Eli Lilly (IC-14 Legacy), Academic Consortia | ARDS, COVID-19, Sepsis, NASH | Affinity/Blockade Assay (Need high-purity sCD14 & GPI-anchored cell line) |
| Bispecifics / ADC / Myeloid Depleter | Early-stage biotech, Emerging Biotechs | Systemic Inflammation, Solid Tumors (TAMs) | Heterodimer Validation (Need Cross-reactive Abs); Internalization Assay (Need stable cell lines via Lentivirus) |
| Small Molecules | Academic Spin-offs | Neuroinflammation | Selectivity Assay (Need High-Purity Recombinant Antigens) |
| Soluble Decoy Receptor | Academic/Preclinical | IBD, Neuroinflammation, ALD | Ligand Binding Assay (Need native glycosylation, HEK293); High-concentration ECD-Fc stability testing |
| TLR4/CD14 Complex Inhibitor | Eritoran developers (legacy) | Viral inflammation, CNS | Heterotrimeric SPR (CD14 + TLR4 + MD-2) binding kinetics |
| Anti-sCD14 Diagnostic | Various Diagnostics | Sepsis Biomarker | Matched Pair Antigen Standards (Native glycosylation critical) |